A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer

Trial Profile

A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Seviteronel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms CLARITY; CLARITY-1
  • Sponsors Innocrin Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017 according to ClinicalTrials.gov record.
    • 02 Jun 2017 Results (data cut off: 4 Oct, 2016; n=30) assessing the stage 1 clinical activity of once daily seviteronel in patients with AR+ triple-negative breast cancer or estrogen receptor (ER)+ breast cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top